Overview |
bsm-33077m-100ul |
CD5 Monoclonal Antibody |
WB, IHC-P, IHC-F, IF, Flow-Cyt |
Human |
Specifications |
Unconjugated |
Mouse |
KLH conjugated synthetic peptide derived from human CD5 |
Monoclonal |
12A8 |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
Target |
921 |
P06127 |
Cell membrane |
T-cell surface glycoprotein CD5; Lymphocyte antigen 1; Ly-1; Lyt-1; CD-5; CD5 antigen; CD 5; CD5 molecule; CD5 antigen (p56 62); CD5_HUMAN; LEU 1; LEU1; Ly12; LyA; Lymphocyte Antigen CD5; Lymphocyte antigen T1/Leu 1; Lymphocyte antigen T1/Leu-1; Lymphocyte glycoprotein T1/Leu1; OTTHUMP00000236973; p56 62; T1. |
This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008] |
Application Dilution |
WB |
=1:500-2000 |
IHC-P |
IHC-P=1:100-500 |
IHC-F |
IHC-F=1:100-500 |
IF |
IF=1:100-500 |
Flow-Cyt |
Flow-Cyt=1ug/Test |